Transthyretin gene silencing therapy in Val50Met familial amyloid polyneuropathy with associated cardiomyopathy

11 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by